U.S. Diversified Financial Stock News

NYSEAM:CET
NYSEAM:CETCapital Markets

3 Reliable Dividend Stocks Offering Up To 7.7% Yield

As the U.S. stock market navigates through a challenging period marked by declining tech shares and fluctuating precious metal prices, investors are increasingly seeking stability amid volatility. In such an environment, dividend stocks can offer a reliable income stream, providing both potential for growth and regular returns that may help cushion against market downturns.
NYSE:ELV
NYSE:ELVHealthcare

Elevance Health (ELV) Margin Compression In Q4 2025 Challenges Bullish Earnings Narratives

Elevance Health (ELV) closed out FY 2025 with Q4 revenue of US$49.7b and basic EPS of US$2.47, alongside net income of US$547m. Over the past six quarters, the company has seen quarterly revenue move from US$45.1b in Q3 2024 to a range between US$48.9b and US$50.7b through 2025, while quarterly EPS shifted from US$4.38 to US$9.64 and then to US$2.47. This sets up an earnings print where margin resilience is front of mind for investors. See our full analysis for Elevance Health. With the...
NasdaqCM:ASPI
NasdaqCM:ASPIChemicals

Assessing ASP Isotopes (ASPI) Valuation After The Renergen Helium Project Production Update

Why the Renergen Helium Project Update Matters for ASP Isotopes (ASPI) ASP Isotopes (ASPI) has given investors a detailed production update on the newly acquired Renergen Helium Project, outlining higher gas throughput, completed plant upgrades, and a timetable toward positive operational cash flow before the end of 2026. See our latest analysis for ASP Isotopes. The Renergen update lands after a volatile stretch, with a 1-day share price return of 1.93% and a 7-day move of 8.77% helping...
OTCPK:VXRT
OTCPK:VXRTBiotechs

A Look At Vaxart’s (VXRT) Valuation As New Norovirus Breastfeeding Study Gains Attention

Why Vaxart’s Norovirus Data Matters for Investors Vaxart (VXRT) has drawn fresh attention after npj Vaccines published Phase 1 data on its single dose, oral bivalent norovirus vaccine in postpartum, breastfeeding women, highlighting immune responses in both mothers and their infants. See our latest analysis for Vaxart. The new npj Vaccines publication comes after a strong 30 day share price return of 83.38% and 90 day share price return of 81.95%. However, the 1 year total shareholder return...
NYSE:BR
NYSE:BRProfessional Services

Assessing Broadridge Financial Solutions (BR) After Recent Share Price Weakness

Curious whether Broadridge Financial Solutions at around US$204.89 is offering fair value or a potential bargain right now? This article walks through the numbers in a clear way so you can judge for yourself. The stock has seen mixed returns, with a 0.9% decline over the last 7 days, a 9.9% decline over the last 30 days and a 7.1% decline year to date. The 3 year and 5 year returns sit at 40.4% and 54.1% respectively, and the 1 year return is a decline of 11.6%. Recent coverage has focused...
NasdaqGS:BUSE
NasdaqGS:BUSEBanks

First Busey (BUSE) Net Interest Margin Steady At 3.5% Challenges Margin Compression Concerns

First Busey (BUSE) has put a fuller year of numbers on the table for FY 2025, with fourth quarter revenue of US$197.8 million and EPS of US$0.63, rounding out trailing twelve month revenue of US$666.8 million and EPS of US$1.49. The company has seen revenue move from US$453.7 million and EPS of US$2.01 on a trailing basis in late 2024 to US$666.8 million and EPS of US$1.49 by the end of 2025. This is setting up a results season where investors are weighing those headline figures against a...
NYSE:TNL
NYSE:TNLHospitality

How Travel + Leisure’s New Orlando HQ Investment At Travel + Leisure (TNL) Has Changed Its Investment Story

Travel + Leisure Co. has opened its new global headquarters at 501 W. Church St. in Downtown Orlando, relocating more than 900 associates and investing over US$36 million in a hybrid-friendly, wellness-focused workplace. The move deepens the company’s ties to Orlando’s urban core while expanding community engagement through the Travel + Leisure Charitable Foundation and local partnerships. We’ll now examine how this Orlando headquarters investment, especially its focus on a modern hybrid...
NYSE:CTVA
NYSE:CTVAChemicals

Is Corteva (CTVA) Pricing Fully Reflects Food Security Tailwinds And Recent Share Gains

If you are wondering whether Corteva's current share price still offers value, it helps to step back and look at what the recent numbers and valuation checks are actually saying. Corteva's share price last closed at US$73.05, with returns of 2.2% over 7 days, 8.0% over 30 days, 7.8% year to date, 13.5% over 1 year and 17.2% over 3 years, plus 84.4% over 5 years. This naturally raises questions about how much of this is already reflected in the valuation. Recent news around Corteva has...
NasdaqGS:IEP
NasdaqGS:IEPIndustrials

Is Icahn Enterprises (IEP) Pricing Reflect Recent Volatility And Ongoing Short Seller Scrutiny?

If you are wondering whether Icahn Enterprises at a last close of US$7.74 offers genuine value or just headline risk, you are not alone. This article is built to help you weigh that up clearly. The stock has been mixed recently, with a 6.0% return over 30 days and a 3.5% return year to date, set against a 2.4% decline over 1 year and much steeper 3 year and 5 year returns of 73.1% and 67.3% declines. These moves sit in the shadow of earlier scrutiny of Icahn Enterprises' structure and short...
NasdaqGM:TVTX
NasdaqGM:TVTXBiotechs

Travere Therapeutics (TVTX) Faces FILSPARI Delay and Legal Scrutiny Is Execution Risk Repricing Ahead?

In recent days, Travere Therapeutics disclosed that the FDA classified additional data for its FILSPARI sNDA as a major amendment, extending the review timeline and setting a new PDUFA action date of April 13, 2026, while multiple law firms announced investigations into potential securities law violations related to the company’s disclosures. This combination of a lengthened regulatory path for a key rare-disease therapy and parallel securities investigations adds an extra layer of...
NYSE:HLI
NYSE:HLICapital Markets

Houlihan Lokey Expands European Footprint As Growth And Valuation Converge

Houlihan Lokey (NYSE:HLI) has expanded its European footprint with the hire of Mark Ward as Managing Director to lead IT Services coverage. The firm has also completed acquisitions in European real estate and corporate finance, adding sector depth and local capabilities. These moves reflect an active push to grow both organically and through acquisitions in key European markets. At a share price of $180.53, Houlihan Lokey has delivered a 3 year return of 94.8% and a 5 year return of 199.2%...
NYSE:FHN
NYSE:FHNBanks

Dividend Hike And Preferred Payouts Might Change The Case For Investing In First Horizon (FHN)

In January 2026, First Horizon Corporation raised its quarterly common dividend to US$0.17 per share and declared regular cash dividends on several preferred stock series, with payments scheduled in April and May 2026 to shareholders of record in March and April. The combination of higher common payouts and continued preferred dividends highlights management’s confidence in the bank’s earnings capacity following stronger fourth-quarter 2025 results. We’ll now examine how the higher common...
NasdaqGS:CERT
NasdaqGS:CERTHealthcare Services

A Look At Certara (CERT) Valuation After Weaker Q4 Bookings And Guidance Trim Under New CEO

Certara (CERT) is back on investors’ radar after Meridian Growth Fund flagged the stock as a relative detractor, citing weaker-than-expected Q4 2025 service bookings and a modest guidance cut. See our latest analysis for Certara. At a share price of $9.40, Certara has seen a 6.21% 1 month share price return but a 17.25% 3 month share price decline. Its 1 year total shareholder return of 32.33% and 5 year total shareholder return of 73.68% point to pressure building over longer periods as...
NasdaqGS:PCH
NasdaqGS:PCHSpecialized REITs

Assessing PotlatchDeltic (PCH) Valuation After Gradual Share Price Momentum And Rich Earnings Multiple

What Recent Performance Says About PotlatchDeltic PotlatchDeltic (PCH) has drawn investor attention after a mix of short term weakness and modest recent gains, with the share price down over the past week but up over the past month and past 3 months. See our latest analysis for PotlatchDeltic. That mix of near term weakness and recent gains fits a broader pattern, with the 30 day share price return of 3.78% and year to date share price return of 4.31% sitting against a 1 year total...
NYSE:HLT
NYSE:HLTHospitality

Is It Too Late To Consider Hilton (HLT) After Its Strong Multi Year Share Price Run

If you are wondering whether Hilton Worldwide Holdings at around US$296 per share still offers value, or if most of the upside is already reflected in the price, this article is for you. The stock has been relatively steady over the short term, with a 0.1% decline over 7 days, a 1.4% return over 30 days, and returns of 1.1% year to date, 17.0% over 1 year, 102.9% over 3 years, and 181.4% over 5 years. Recent news coverage has focused on Hilton's position as a major global hotel operator and...
NYSE:NFG
NYSE:NFGGas Utilities

National Fuel Gas Links Higher CEO Pay To New Government Contracts

National Fuel Gas (NYSE:NFG) disclosed a significant increase in CEO compensation in a recent SEC filing. The company also announced new government contract awards, expanding its role as an energy supplier to public sector customers. These developments update investors on executive pay structures and newly secured business commitments. National Fuel Gas, traded as NYSE:NFG, operates across natural gas exploration, production, gathering, and utility services. For you as a shareholder or...
NasdaqGS:PRVA
NasdaqGS:PRVAHealthcare

Should UnitedHealth’s Medicare Outlook And Restructuring Require Action From Privia Health Group (PRVA) Investors?

Recently, sector-wide concerns emerged after UnitedHealth Group issued a cautious revenue outlook, outlined major restructuring plans, and flagged pressure from proposed flat Medicare Advantage payment rates, weighing on peers such as Privia Health Group. This reaction came even though Privia Health had earlier highlighted strong Accountable Care Organization Medicare shared savings and increased its 2025 Adjusted EBITDA guidance, which had been viewed positively by analysts. Next, we will...
NasdaqGS:NVMI
NasdaqGS:NVMISemiconductor

Is It Too Late To Consider Nova (NVMI) After Its Share Price Surges Over 100%?

If you are wondering whether Nova's recent share price puts it at a premium or leaves some value on the table, this article will walk through what the current numbers are saying about the stock. Nova's share price recently closed at US$487.18, with returns of 5.2% over 7 days, 45.9% over 30 days, 40.3% year to date and 109.6% over 1 year, while the 3 year return is over 4x and the 5 year return is very large. Recent coverage has focused on how Nova fits into the semiconductor equipment space...
NasdaqGS:MANH
NasdaqGS:MANHSoftware

Manhattan Associates (MANH) Premium P/E Faces Slower 0.7% EPS Growth Narrative Challenge

Manhattan Associates (MANH) has wrapped up FY 2025 with fourth quarter revenue of US$270.4 million and basic EPS of US$0.87, alongside net income excluding extra items of US$52.0 million. Trailing 12 month revenue came in at about US$1.1 billion with basic EPS of US$3.64. Over recent quarters, the company has seen revenue range from US$262.8 million to US$275.8 million and quarterly basic EPS move between US$0.86 and US$0.97, set against trailing 12 month EPS that has stayed around the mid...
NasdaqCM:QUBT
NasdaqCM:QUBTTech

How Quantum Computing’s Photonics Push And Revenue Momentum At Quantum Computing (QUBT) Has Changed Its Investment Story

In recent months, Quantum Computing Inc. has reported rapid revenue momentum, strong cash reserves, and plans to acquire Luminar Semiconductor’s remaining assets for about US$22,000,000 to deepen its photonics capabilities. The company is positioning itself as an integrated quantum hardware, software, and cybersecurity platform, while investors weigh execution risks and uncertainty over which quantum technology will ultimately lead the market. We’ll now examine how Quantum Computing’s...
NasdaqCM:VRRM
NasdaqCM:VRRMProfessional Services

Is Verra Mobility (VRRM) Attractive After Recent Share Price Weakness?

If you are wondering whether Verra Mobility's current share price lines up with its underlying value, this article will walk you through the key signals that matter most. The stock closed at US$19.84, with returns of a 9.8% decline over 7 days, a 12.7% decline over 30 days and an 11.2% decline year to date. The 1-year return is a 24.8% decline and the 3 and 5-year returns are 25.3% and 41.4% respectively. These mixed returns sit against a backdrop where investors are paying closer attention...
NYSE:LOW
NYSE:LOWSpecialty Retail

Is Lowe's (LOW) Fairly Priced After Recent Share Price Rebound?

If you are wondering whether Lowe's Companies is attractively priced at its current level, you are not alone. The stock often gets attention from investors trying to work out if the market is being too cautious or too optimistic. The share price recently closed at US$269.42, with a 10.5% return over the last 30 days, a 9.1% return year to date and a 5.0% return over the last year, alongside a 2.8% decline over the past week and a 74.1% return over five years. Recent news coverage has focused...
NYSE:BOH
NYSE:BOHBanks

Assessing Bank of Hawaii (BOH) Valuation After Earnings Beat And Strengthened Outlook

Bank of Hawaii (BOH) is back in focus after fourth quarter 2025 results topped Wall Street expectations, with higher net interest income, wider net interest margin, disciplined costs, and an affirmed US$0.70 quarterly dividend. See our latest analysis for Bank of Hawaii. Investors have reacted positively to the earnings beat and ongoing buybacks, with the share price at US$74.14 and a 90 day share price return of 14.17%. The 5 year total shareholder return of 14.42% suggests steadier long...